融合靶向前列腺穿刺活检中每个感兴趣区应采集多少针?一项回顾性单中心统计模拟研究
该回顾性单中心研究纳入2017年1月至2022年6月在本机构接受靶向穿刺(每个感兴趣区4针)联合系统12针前列腺穿刺的483例患者,通过统计模拟评估每个感兴趣区取1、2、3或4针时临床显著前列腺癌(csPC)的检出率。靶向穿刺单独分析时,csPC检出率随针数增加而升高(1针21%至4针31%);联合系统穿刺时,各针数间csPC检出率无显著差异。
要点
- 靶向穿刺单独使用时,每个感兴趣区取2针或以上对csPC的检出优于1针。
- 靶向联合系统穿刺时,增加每个感兴趣区的针数对csPC检出的提升作用减弱。
- 靶向穿刺单独分析中,csPC检出率1针21%、2针26%、3针29%、4针31%。
核心结论
- 若仅行靶向穿刺而不联合系统穿刺,每个感兴趣区取2针或以上在检测csPC方面优于取1针。
- 当靶向穿刺与系统穿刺联合进行时,增加每个感兴趣区的针数对csPC检出的提升作用减弱。
研究设计与样本
- 回顾性单中心研究,纳入2017年1月至2022年6月在本机构接受靶向前列腺穿刺(每个感兴趣区4针)联合系统12针前列腺穿刺的患者,共483例。
- 采用统计模拟构建每个感兴趣区取1、2、3或4针的场景,并分别计算靶向穿刺及靶向联合系统穿刺的Grade Group≥2前列腺癌(csPC)检出率。
- 穿刺途径包括经直肠(96%)和经会阴(4%)。
主要发现
- 靶向穿刺单独分析时,csPC检出率在取1针时为21%,取2针时为26%(P = .048),取3针时为29%(P = .002),取4针时为31%(P < .001)。
- 靶向联合系统穿刺分析时,csPC检出率在取1针时为33%,取2针时为35%(P = .4),取3针时为37%(P = .2),取4针时为38%(P = .12)。
临床怎么用
- 作者结论认为,若仅行靶向穿刺而不联合系统穿刺,每个感兴趣区取2针或以上优于取1针。
- 作者结论认为,当靶向穿刺与系统穿刺联合进行时,增加每个感兴趣区针数对csPC检出的提升作用减弱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine how many cores should be collected per region of interest (ROI) in magnetic resonance imaging-guided fusion prostate biopsy. Magnetic resonance imaging-guided targeted prostate biopsy has led to improved detection of clinically significant prostate cancer (csPC); however, data is limited regarding the optimal number of biopsy cores that should be taken. An ideal number of cores maximizes clinically significant cancer detection while minimizing cost, discomfort, and procedure time. METHODS: Patients receiving targeted prostate biopsy (4 cores per ROI) combined with systematic 12-core prostate at our institution between January 2017 and June 2022 were retrospectively identified. Statistical simulation was used to model scenarios in which 1, 2, 3, or 4 cores were taken from the ROI, and the rate of grade group ≥2 prostate cancer (csPC) detection was determined for targeted and combined targeted plus systematic biopsy. RESULTS: 483 patients were identified. Transrectal (96%) and transperineal (4%) biopsies were included. For targeted biopsy, csPC was present in 21% (1 core), 26% (2 cores; P = .048), 29% (3 cores; P = .002), and 31% (4 cores; P < .001) of cases. For combined biopsy, csPC was present in 33% (1 core), 35% (2 cores; P = .4), 37% (3 cores; P = .2), and 38% (4 cores; P = .12) of cases. CONCLUSION: If targeted biopsy is performed without systematic biopsy, 2 or more cores is superior to 1 core for detecting csPC. This effect is mitigated when targeted and systematic biopsy are combined.
引用
- Brodsky CN, Daignault-Newton S, Davenport MS, et al. How Many Cores Should Be Collected per Region of Interest in Fusion Targeted Prostate Biopsy? A Retrospective Single Institution Statistical Simulation. Urology. 2024. PMID: 39730113. doi:10.1016/j.urology.2024.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。